Literature DB >> 30975647

A Direct Podocalyxin-Dynamin-2 Interaction Regulates Cytoskeletal Dynamics to Promote Migration and Metastasis in Pancreatic Cancer Cells.

Bin Sheng Wong1,2, Daniel J Shea1, Panagiotis Mistriotis1,2, Soontorn Tuntithavornwat1, Robert A Law1, Jake M Bieber1, Lei Zheng3, Konstantinos Konstantopoulos4,2,3,5,6.   

Abstract

The sialoglycoprotein podocalyxin is absent in normal pancreas but is overexpressed in pancreatic cancer and is associated with poor clinical outcome. Here, we investigate the role of podocalyxin in migration and metastasis of pancreatic adenocarcinomas using SW1990 and Pa03c as cell models. Although ezrin is regarded as a cytoplasmic binding partner of podocalyxin that regulates actin polymerization via Rac1 or RhoA, we did not detect podocalyxin-ezrin association in pancreatic cancer cells. Moreover, depletion of podocalyxin did not alter actin dynamics or modulate Rac1 and RhoA activities in pancreatic cancer cells. Using mass spectrometry, bioinformatics analysis, coimmunoprecipitation, and pull-down assays, we discovered a novel, direct binding interaction between the cytoplasmic tail of podocalyxin and the large GTPase dynamin-2 at its GTPase, middle, and pleckstrin homology domains. This podocalyxin-dynamin-2 interaction regulated microtubule growth rate, which in turn modulated focal adhesion dynamics and ultimately promoted efficient pancreatic cancer cell migration via microtubule- and Src-dependent pathways. Depletion of podocalyxin in a hemispleen mouse model of pancreatic cancer diminished liver metastasis without altering primary tumor size. Collectively, these findings reveal a novel mechanism by which podocalyxin facilitates pancreatic cancer cell migration and metastasis. SIGNIFICANCE: These findings reveal that a novel interaction between podocalyxin and dynamin-2 promotes migration and metastasis of pancreatic cancer cells by regulating microtubule and focal adhesion dynamics. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30975647      PMCID: PMC6548656          DOI: 10.1158/0008-5472.CAN-18-3369

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  52 in total

1.  The glomerular epithelial cell anti-adhesin podocalyxin associates with the actin cytoskeleton through interactions with ezrin.

Authors:  Robert A Orlando; Tetsuro Takeda; Beverly Zak; Sandra Schmieder; Vivian M Benoit; Tammie McQuistan; Heinz Furthmayr; Marilyn G Farquhar
Journal:  J Am Soc Nephrol       Date:  2001-08       Impact factor: 10.121

2.  Electrostatic cell-surface repulsion initiates lumen formation in developing blood vessels.

Authors:  Boris Strilić; Jan Eglinger; Michael Krieg; Martin Zeeb; Jennifer Axnick; Pavel Babál; Daniel J Müller; Eckhard Lammert
Journal:  Curr Biol       Date:  2010-10-21       Impact factor: 10.834

3.  Podocalyxin is a CD34-related marker of murine hematopoietic stem cells and embryonic erythroid cells.

Authors:  Regis Doyonnas; Julie S Nielsen; Shierley Chelliah; Erin Drew; Takahiko Hara; Atsushi Miyajima; Kelly M McNagny
Journal:  Blood       Date:  2005-02-08       Impact factor: 22.113

4.  Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guérin.

Authors:  Joan Palou; Ferrán Algaba; Irene Vera; Oscar Rodriguez; Humberto Villavicencio; Marta Sanchez-Carbayo
Journal:  Eur Urol       Date:  2008-10-09       Impact factor: 20.096

5.  Podocalyxin in human haematopoietic cells.

Authors:  Laura Kerosuo; Eeva Juvonen; Riitta Alitalo; Mikhail Gylling; Dontscho Kerjaschki; Aaro Miettinen
Journal:  Br J Haematol       Date:  2004-03       Impact factor: 6.998

Review 6.  The prothrombotic activity of cancer cells in the circulation.

Authors:  Annachiara Mitrugno; Garth W Tormoen; Peter Kuhn; Owen J T McCarty
Journal:  Blood Rev       Date:  2015-07-14       Impact factor: 8.250

7.  Podocalyxin-like protein is an E-/L-selectin ligand on colon carcinoma cells: comparative biochemical properties of selectin ligands in host and tumor cells.

Authors:  Susan N Thomas; Ronald L Schnaar; Konstantinos Konstantopoulos
Journal:  Am J Physiol Cell Physiol       Date:  2008-12-31       Impact factor: 4.249

8.  Physical confinement alters tumor cell adhesion and migration phenotypes.

Authors:  Eric M Balzer; Ziqiu Tong; Colin D Paul; Wei-Chien Hung; Kimberly M Stroka; Amanda E Boggs; Stuart S Martin; Konstantinos Konstantopoulos
Journal:  FASEB J       Date:  2012-06-15       Impact factor: 5.191

9.  Increased expression of the large GTPase dynamin 2 potentiates metastatic migration and invasion of pancreatic ductal carcinoma.

Authors:  R D Eppinga; E W Krueger; S G Weller; L Zhang; H Cao; M A McNiven
Journal:  Oncogene       Date:  2011-08-15       Impact factor: 9.867

10.  Identification of podocalyxin-like protein as a high endothelial venule ligand for L-selectin: parallels to CD34.

Authors:  C Sassetti; K Tangemann; M S Singer; D B Kershaw; S D Rosen
Journal:  J Exp Med       Date:  1998-06-15       Impact factor: 14.307

View more
  16 in total

1.  Giant obscurin regulates migration and metastasis via RhoA-dependent cytoskeletal remodeling in pancreatic cancer.

Authors:  Soontorn Tuntithavornwat; Daniel J Shea; Bin Sheng Wong; Talia Guardia; Se Jong Lee; Christopher L Yankaskas; Lei Zheng; Aikaterini Kontrogianni-Konstantopoulos; Konstantinos Konstantopoulos
Journal:  Cancer Lett       Date:  2021-11-23       Impact factor: 9.756

2.  Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer.

Authors:  Annika Eurola; Ari Ristimäki; Harri Mustonen; Anna-Maria Nurmi; Jaana Hagström; Caj Haglund; Hanna Seppänen
Journal:  Sci Rep       Date:  2021-05-10       Impact factor: 4.379

3.  The Expression of Dynamin 1, 2, and 3 in Human Hepatocellular Carcinoma and Patient Prognosis.

Authors:  Mei Tian; Xiuchun Yang; Yanfang Li; Sen Guo
Journal:  Med Sci Monit       Date:  2020-06-23

4.  Dynamin 2 Is Correlated with Recurrence and Poor Prognosis of Papillary Thyroid Cancer.

Authors:  Ning Ren; Zhenmin Tian; Hongmei Sun; Xiaofei Lu
Journal:  Med Sci Monit       Date:  2020-08-22

5.  RAC1 Involves in the Radioresistance by Mediating Epithelial-Mesenchymal Transition in Lung Cancer.

Authors:  Shiming Tan; Pin Yi; Heran Wang; Longzheng Xia; Yaqian Han; Hui Wang; Biao Zeng; Lu Tang; Qing Pan; Yutong Tian; Shan Rao; Linda Oyang; Jiaxin Liang; Jinguan Lin; Min Su; Yingrui Shi; Qianjin Liao; Yujuan Zhou
Journal:  Front Oncol       Date:  2020-04-28       Impact factor: 6.244

6.  Dynamin 2 interacts with α-actinin 4 to drive tumor cell invasion.

Authors:  Kevin M Burton; Hong Cao; Jing Chen; Li Qiang; Eugene W Krueger; Katherine M Johnson; William R Bamlet; Lizhi Zhang; Mark A McNiven; Gina L Razidlo
Journal:  Mol Biol Cell       Date:  2020-01-22       Impact factor: 4.138

7.  PODO447: a novel antibody to a tumor-restricted epitope on the cancer antigen podocalyxin.

Authors:  Diana Canals Hernaez; Michael R Hughes; Pamela Dean; Peter Bergqvist; Ismael Samudio; Ola Blixt; Katharina Wiedemeyer; Yicong Li; Chris Bond; Eric Cruz; Martin Köbel; Blake Gilks; Calvin D Roskelley; Kelly M McNagny
Journal:  J Immunother Cancer       Date:  2020-11       Impact factor: 13.751

8.  Knockdown of α2,3-Sialyltransferases Impairs Pancreatic Cancer Cell Migration, Invasion and E-selectin-Dependent Adhesion.

Authors:  Pedro Enrique Guerrero; Laura Miró; Bin S Wong; Anna Massaguer; Neus Martínez-Bosch; Rafael de Llorens; Pilar Navarro; Konstantinos Konstantopoulos; Esther Llop; Rosa Peracaula
Journal:  Int J Mol Sci       Date:  2020-08-28       Impact factor: 5.923

Review 9.  A review of Dynamin 2 involvement in cancers highlights a promising therapeutic target.

Authors:  Delphine Trochet; Marc Bitoun
Journal:  J Exp Clin Cancer Res       Date:  2021-07-22

10.  Dorsoventral polarity directs cell responses to migration track geometries.

Authors:  Emily O Wisniewski; Panagiotis Mistriotis; Kaustav Bera; Robert A Law; Jitao Zhang; Milos Nikolic; Michael Weiger; Maria Parlani; Soontorn Tuntithavornwat; Alexandros Afthinos; Runchen Zhao; Denis Wirtz; Petr Kalab; Giuliano Scarcelli; Peter Friedl; Konstantinos Konstantopoulos
Journal:  Sci Adv       Date:  2020-07-31       Impact factor: 14.957

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.